In a field rife with disagreement, STS, AATS, and others say the European guidelines got it right when it comes to CABG.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Clinicians and patients alike have lost homes and possessions, but cardiovascular care in Los Angeles remains robust.

Fitness doesn’t make people immune to atherosclerosis, but what to do with the finding in asymptomatic patients is uncertain.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Vinod Thourani and Larry Epstein explore the current field of tricuspid intervention as well as challenges within lead ...

An app-based program failed to boost function for most at 3 months, but positive signs were seen in women and after CABG.

In the year before amputation, a deep divide was seen between patients who got specialist care and those who did not.

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Two new trials saw no impact of thrombolytics in reducing disability at 90 days, but some positive signals offer hope.